Considering, as you stated, 'the initial 11.5c and increase this by a measly few cents were lowball offer' 'but the price is nearly double' must certainly be given due consideration as to the prospective, in the course of time (on the cusp of medical adoption/acceptance). The significance of the technology in terms of health outcomes and the return to shareholders is at this point exponential.
Ann: Second Supplementary Scheme Booklet, page-108
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
